Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Bevacizumab plus sunitinib in metastatic RCC leads to 'supra-additive' toxicity

    • 7 Accesses

    This is a preview of subscription content, log in to check access.

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Bevacizumab plus sunitinib in metastatic RCC leads to 'supra-additive' toxicity. React. Wkly. 1243, 2 (2009). https://doi.org/10.2165/00128415-200912430-00002

    Download citation

    Keywords

    • Vascular Endothelial Growth Factor
    • Renal Cell Carcinoma
    • Bevacizumab
    • Thrombocytopenia
    • Proteinuria